PMC8702428_01
Initial chest computed tomography of the patient revealed a large mass in the right upper lobe with enlarged mediastinal lymph node and malignant pleural effusion (A,B).
fsurg-08-659983-g0001.jpg
PMC8702428_01_fsurg-08-659983-g0001.jpg
F1
TTF-1(+), CK18(+), CK5/6(-), P63(scattered +), CK14(-), CDX-2(-), CD56(+), CgA(-), Sgn(-), Ki-67(~50%)] in the right upper lobe with enlarged ipsilateral mediastinal lymph node and MPE confirmed by cytological examination of the fluid via both cell block and smear from the collected sample by thoracentesis, which was not further confirmed by pleural biopsy (cT3N2M1a, IVa) (Figure 1). The patient was generally in normal condition but was found to have type two diabetes mellitus with an Eastern Cooperative Oncology Group score of 1.
Preoperative chest computed tomography of the patient showing excellent response to neoadjuvant targeted therapy (A-C).
fsurg-08-659983-g0002.jpg
PMC8702428_01_fsurg-08-659983-g0002.jpg
F2
After taking gefitinib for 4 months, the patient was re-evaluated comprehensively and an excellent radiographic response to gefitinib was found on his chest computed tomography scan (Figure 2).
Recent positron emission tomography/computed tomography of the patient shows no sign of recurrence.
fsurg-08-659983-g0003.jpg
PMC8702428_01_fsurg-08-659983-g0003.jpg
F3
The patient's recent PET/CT scan (October 2021) still revealed no sign of recurrence (Figure 3), and he is still alive without disease for 62 months after surgery (disease-free survival: 62 months).
Treatment timeline of the patient in our case.
fsurg-08-659983-g0004.jpg
PMC8702428_01_fsurg-08-659983-g0004.jpg
F4
The whole treatment timeline of the patient in our case was summarized in Figure 4.